https://www.selleckchem.com/products/TWS119.html
5% in noncarriers), but there was no significant difference in the regional nodal status (58.5-63% with cN. Contralateral breast cancer developed in 26.5% of BRCA1/2 mutation carriers and in 14% of noncarriers. Other primary cancers were also slightly more common in BRCA1/2 mutation carriers (16.5% vs 9.5%). The performed analysis did not show any significant differences between the groups in recurrence-free survival (p=0.312). There was no significant difference between patients with or without BRCA1/2 mutation as regards overall surv
Like
Comment
Share
